News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Kidney problems news

Show

From To
Organ transplants
Survival and outcome analysis shows that selected HIV-positive patients are good candidates for liver and kidney transplant

Liver and kidney transplant can be justified for carefully selected HIV-positive patients, researchers from the United States show in AIDS. Transplant improved the chances of survival for HIV-positive

Published
11 February 2016
By
Michael Carter
Organ transplants
Johns Hopkins approved to perform first HIV-positive to HIV-positive organ transplants in U.S.

Johns Hopkins recently received approval from the United Network for Organ Sharing to be the first hospital in the United States to perform HIV-positive to HIV-positive organ transplants. The institution will be the first in the nation to do an HIV-positive kidney transplant and the first in the world to execute an HIV-positive liver transplant.

Published
09 February 2016
From
Johns Hopkins Medicine
New and experimental HIV treatments
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART

Two-drug antiretroviral therapy (ART) consisting of ritonavir-boosted atazanavir and lamivudine has comparable or better virological efficacy than traditional three-drug therapy based on ritonavir/atazanavir, according to a poster presentation at

Published
30 November 2015
By
Michael Carter
Organ transplants
NIH publishes criteria for research on organ transplantation between people with HIV infection

​In a Federal Register notice on Nov. 25, 2015, the U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection.

Published
27 November 2015
From
National Institutes of Health
HIV treatment
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved

The long-running controversy over when to start antiretroviral therapy (ART) has been definitively answered, but research is still needed to fully understand the implications of the large START

Published
23 October 2015
By
Liz Highleyman
New and experimental HIV treatments
Studies continue to support tenofovir alafenamide combination pill as it nears US approval

A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression for people switching from other combinations and was associated with improved kidney function and bone health,

Published
19 October 2015
By
Liz Highleyman
Side-effects
TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

Published
12 October 2015
From
Monthly Prescribing Reference
Delivery of care
High standards of care associated with reduced mortality risk of patients with HIV

Quality of care (QOC) in the first twelve months after entering HIV care is associated with longer-term mortality risk, investigators from the US Department of Veterans Affairs report

Published
28 September 2015
By
Michael Carter
New and experimental HIV treatments
Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

Published
04 September 2015
From
HIVandHepatitis.com
HIV treatment
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
← Prev1...45678...15Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.